<?xml version="1.0" encoding="ISO-8859-1" ?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
   <channel>
      <title>MiamiHerald.com: Press Releases - Biotechnology</title>
<link>http://www.miamiherald.com/965/index.html</link>
<image>
<title>MiamiHerald.com: Press Releases - Biotechnology</title>
<url>http://media.miamiherald.com/images/logos/rss_sitelogo.gif</url>
        <link>http://www.miamiherald.com/965/index.html</link>
<width>140</width>
<height>25</height>
</image>
      <description>News, sports and entertainment from MiamiHerald.com</description>
      <language>en-us</language>
      <copyright>Copyright 2008 MiamiHerald.com</copyright>

      <category domain="MiamiHerald.com">Press Releases - Biotechnology</category>
      <ttl>60</ttl>
        <pubDate>Fri, 16 May 2008 16:47:05 EDT</pubDate>
      <docs>http://blogs.law.harvard.edu/tech/rss</docs>
      <generator>McClatchy Interactive's PubSys</generator>      
      <managingEditor>miamifeedback@miamiherald.com</managingEditor>

                
        
        
    
        <item>
    <title>Former CMS Administrator: &quot;&amp;#39;Blunt Instrument&amp;#39; Policies an Increasingly Bad Fit in Era of Personalized Health Care&quot;</title>
    <link>http://www.miamiherald.com/965/story/536202.html</link>
    <guid>http://www.miamiherald.com/965/story/536202.html</guid>
    <pubDate>Fri, 16 May 2008 16:45 EDT</pubDate>
    <description> Recent legislative
emphasis on price negotiation and physician reimbursement as a means to reduce
health care costs are nothing more than &amp;quot;short term patches&amp;quot; that hold no
potential for truly reforming health care, former Centers for Medicare and
Medicaid Services (CMS) Administrator Dr. Mark McClellan told hundreds of
health care decision makers today in delivering the keynote address at Medco
Health Solutions, Inc. (NYSE: MHS) 2008 Drug Trend &amp;quot;Predictions&amp;quot; Symposium.</description>
</item>    

                
        
        
                    
        
        
                      
<item>
    <title>Urologix Launches New CTC Advance Catheter at 2008 American Urological Association Annual Meeting</title>
    <link>http://www.miamiherald.com/965/story/535934.html</link>
    <guid>http://www.miamiherald.com/965/story/535934.html</guid>
    <pubDate>Fri, 16 May 2008 14:10 EDT</pubDate>
    <description>Urologix(R), Inc. (NASDAQ:ULGX) announced today it is launching
its next generation Cooled ThermoTherapy(TM) (CTT) treatment catheter,
CTC Advance(TM) at the 2008 American Urological Association Annual
Meeting in Orlando, Florida being held May 17-22, 2008. Urologix is
the pioneer of Cooled ThermoTherapy for the treatment of enlarged
prostate disease in the comfortable setting of a physician&amp;#39;s office.
</description>
</item>
                   
<item>
    <title>CapMed Executive to Discuss 'Key to Personal Health Record Adoption' at TEPR 2008 Conference</title>
    <link>http://www.miamiherald.com/965/story/535893.html</link>
    <guid>http://www.miamiherald.com/965/story/535893.html</guid>
    <pubDate>Fri, 16 May 2008 13:15 EDT</pubDate>
    <description>CapMed, a division of Bio-Imaging Technologies, Inc. (NASDAQ:
BITI) and a leader in interactive personal health management
solutions, today announced that Mary Ellen Zipper, Director of Client
Relations, will educate attendees about the &amp;quot;Key to Personal Health
Record Adoption&amp;quot; at this year&amp;#39;s TEPR conference in Fort Lauderdale,
Florida, on May 20th at 8 a.m. and 2 p.m. in Room 204.
</description>
</item>
                   
<item>
    <title>Vanguard Urologic Institute First to Implant AxoGen's Avance Nerve Graft Using a Robot for Cavernous Nerve Repair</title>
    <link>http://www.miamiherald.com/965/story/535863.html</link>
    <guid>http://www.miamiherald.com/965/story/535863.html</guid>
    <pubDate>Fri, 16 May 2008 12:20 EDT</pubDate>
    <description>In 2007, more than 200,000 men were newly diagnosed with prostate
cancer, with many of them undergoing radical prostatectomies. During a
radical prostatectomy, care is taken to remove the cancer and the
prostate while preserving the surrounding nerves. The cavernous
nerves, which lie next to the prostate, are essential for erectile
function, and to a lesser degree, urinary continence.
</description>
</item>
                   
<item>
    <title>Accentia Biopharmaceuticals Reports Fiscal Second Quarter Financial Results</title>
    <link>http://www.miamiherald.com/965/story/535734.html</link>
    <guid>http://www.miamiherald.com/965/story/535734.html</guid>
    <pubDate>Fri, 16 May 2008 10:25 EDT</pubDate>
    <description>Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today
that the Company has filed its Quarterly Report (Form 10-Q) with the
SEC, reporting the results of its operations, including consolidated
results with its majority-owned subsidiary, Biovest International,
Inc. (OTCBB:BVTI), for its second fiscal quarter ended March 31, 2008.
The Company also announced that it is scheduled to present at the
Jefferies &amp;amp; Co. 2nd Annual Healthcare Conference in New York City.
</description>
</item>
                   
<item>
    <title>Catalyst Pharmaceutical Partners Reports First Quarter 2008 Financial Results</title>
    <link>http://www.miamiherald.com/965/story/535615.html</link>
    <guid>http://www.miamiherald.com/965/story/535615.html</guid>
    <pubDate>Fri, 16 May 2008 08:10 EDT</pubDate>
    <description> Catalyst
Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results
for the quarter ended March 31, 2008. The Company also announced the addition
of Frank Greenway, M.D. to Catalyst&amp;#39;s Scientific Advisory Board and the
retention of Andrew Forman as a Business Development and Investor Relations
Consultant.</description>
</item>
                   
<item>
    <title>RTI Biologics Announces Successful Implantation of First Fresh-Stored Osteochondral Allograft</title>
    <link>http://www.miamiherald.com/965/story/534705.html</link>
    <guid>http://www.miamiherald.com/965/story/534705.html</guid>
    <pubDate>Thu, 15 May 2008 16:45 EDT</pubDate>
    <description>RTI Biologics, Inc. (RTI) (Nasdaq:RTIX), the Florida-based
processor of orthopedic, dental, hernia and other biologic implants,
announces the successful implantation of its first fresh-stored
osteochondral (OC) allograft in Arkansas last Monday.
</description>
</item>
                   
<item>
    <title>Bioheart, Inc. Announces Financial Results for First Quarter 2008</title>
    <link>http://www.miamiherald.com/965/story/534658.html</link>
    <guid>http://www.miamiherald.com/965/story/534658.html</guid>
    <pubDate>Thu, 15 May 2008 16:15 EDT</pubDate>
    <description> Bioheart, Inc.
(Nasdaq: BHRT) a biotechnology company that is focused on the development of
autologous (patient-derived) cell therapies and devices for the treatment of
chronic and acute heart damage, today announced financial results for the
quarter ended March 31, 2008.</description>
</item>
                   
<item>
    <title>Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute</title>
    <link>http://www.miamiherald.com/965/story/534163.html</link>
    <guid>http://www.miamiherald.com/965/story/534163.html</guid>
    <pubDate>Thu, 15 May 2008 09:10 EDT</pubDate>
    <description> Tigris Pharmaceuticals, Inc.
announced today the execution of a Cooperative Research and Development
Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on
clinical and preclinical development of AFP-464, an aminoflavone currently in
Phase I development.  AFP-464 is converted to metabolites which bind
covalently to DNA, resulting in p53 activation and apoptosis.</description>
</item>
                   
<item>
    <title>AEterna Zentaris to Present at Upcoming Rodman &amp; Renshaw Global Healthcare Conference and AUA Annual Meeting</title>
    <link>http://www.miamiherald.com/965/story/534072.html</link>
    <guid>http://www.miamiherald.com/965/story/534072.html</guid>
    <pubDate>Thu, 15 May 2008 07:40 EDT</pubDate>
    <description></description>
</item>
                   
<item>
    <title>IVAX Diagnostics Reports First Quarter Results</title>
    <link>http://www.miamiherald.com/965/story/532582.html</link>
    <guid>http://www.miamiherald.com/965/story/532582.html</guid>
    <pubDate>Wed, 14 May 2008 08:28 EDT</pubDate>
    <description>IVAX Diagnostics, Inc. (AMEX:IVD) reported its financial results
for the first quarter of 2008. For the quarter, IVAX Diagnostics
recorded net income of $345,000, or earnings of $0.01 per share,
compared to net loss of $238,000, or loss of $0.01 per share, in the
first quarter of 2007. Net revenues for the first quarter of 2008 were
$5,242,000, an increase of $296,000, or 6%, from the first quarter of
2007.
</description>
</item>
                   
<item>
    <title>Dyadic Announces Mailing of Notice of Annual Stockholders Meeting to Be Held On Friday, June 20, 2008</title>
    <link>http://www.miamiherald.com/965/story/531715.html</link>
    <guid>http://www.miamiherald.com/965/story/531715.html</guid>
    <pubDate>Tue, 13 May 2008 16:42 EDT</pubDate>
    <description>Dyadic International, Inc. (the &amp;quot;Company&amp;quot;) announced today that,
in accordance with the Order of the Delaware Court of Chancery in
Emalfarb v. Dyadic International, Inc. (C.A. No. 3353-VCP) previously
reported in a Current Report on Form 8-K filed with the SEC on April
15, 2008, on Friday, May 9, 2008, it mailed to its stockholders of
record as of the close of business on April 23, 2008 a notice of its
annual meeting of stockholders to be held on Friday, June 20, 2008, at
10:00 a.m., EDT, at the Doubletree Hotel, 4431 PGA Boulevard, Palm
Beach Gardens, Florida 33410.
</description>
</item>
                   
<item>
    <title>NeoStem to Expand Stem Cell Collection Center Network to Florida</title>
    <link>http://www.miamiherald.com/965/story/531193.html</link>
    <guid>http://www.miamiherald.com/965/story/531193.html</guid>
    <pubDate>Tue, 13 May 2008 08:58 EDT</pubDate>
    <description> NeoStem, Inc. (Amex: NBS),
which is pioneering the pre-disease collection, processing and long-term
storage of adult stem cells for future medical need, today announced that a
site has been secured for a new stem cell collection center in Coral Gables,
Florida, a suburb of Miami.</description>
</item>
                   
<item>
    <title>Dawning Technologies, Inc. Releases JavaLin/PDI Portable Device Interface</title>
    <link>http://www.miamiherald.com/965/story/530093.html</link>
    <guid>http://www.miamiherald.com/965/story/530093.html</guid>
    <pubDate>Mon, 12 May 2008 13:06 EDT</pubDate>
    <description> Dawning Technologies, Inc.
announces the release of their latest small footprint interface device in the
new JavaLin/PDI Portable Device Interface.  The JavaLin/PDI is the fifth
generation of intelligent clinical interfaces from Dawning and provides an
unparalleled range of features and capabilities primarily aimed at the
connection of clinical instruments to information systems. Combining the power
of JResultNet Interface Engine Software, embedded within the JavaLin/PDI, with
a flexible hardware design, the JavaLin/PDI supports a variety of industry
standard communication protocols and can run any of the applications in
Dawning&amp;#39;s Java Driver Library, now available for more than 400 instruments.</description>
</item>
                   
<item>
    <title>Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research</title>
    <link>http://www.miamiherald.com/965/story/527498.html</link>
    <guid>http://www.miamiherald.com/965/story/527498.html</guid>
    <pubDate>Fri, 09 May 2008 15:30 EDT</pubDate>
    <description> The Cancer Research Alliance, an
organization comprised of 12 of the nation&amp;#39;s best cancer centers including
Moffitt Cancer Center, is asking all 303 million Americans to exercise their
power over cancer by stepping up and donating $1 to cancer research efforts
this Mother&amp;#39;s Day through Father&amp;#39;s Day.</description>
</item>
                   
<item>
    <title>AACE Calls for New Standards for Safer Insulin Pump Use</title>
    <link>http://www.miamiherald.com/965/story/527242.html</link>
    <guid>http://www.miamiherald.com/965/story/527242.html</guid>
    <pubDate>Fri, 09 May 2008 12:22 EDT</pubDate>
    <description>&amp;quot;The American Association of Clinical Endocrinologists applauds
the FDA&amp;#39;s efforts to protect the safety of children and adolescents
who are using insulin pumps,&amp;quot; said Dr. Richard Hellman, the
Association&amp;#39;s President.
</description>
</item>
                   
<item>
    <title>Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session</title>
    <link>http://www.miamiherald.com/965/story/525719.html</link>
    <guid>http://www.miamiherald.com/965/story/525719.html</guid>
    <pubDate>Thu, 08 May 2008 10:07 EDT</pubDate>
    <description> Alpharma Inc. (NYSE: ALO), a
global specialty pharmaceutical company, today announced results from clinical
trials that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with
sequestered naltrexone hydrochloride) capsules demonstrated clinically
relevant features addressing abuse liability alongside a promising safety and
efficacy profile.  The Phase I and II studies, presented at the 27th Annual
Scientific Session of the American Pain Society, examined the effects of
ALO-01 when crushed -- a common method of abuse -- among recreational drug
users and when taken whole, as intended, by chronic pain patients.</description>
</item>
                   
<item>
    <title>Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions</title>
    <link>http://www.miamiherald.com/965/story/525639.html</link>
    <guid>http://www.miamiherald.com/965/story/525639.html</guid>
    <pubDate>Thu, 08 May 2008 08:38 EDT</pubDate>
    <description> Alpharma Inc. (NYSE: ALO), a
leading global specialty pharmaceutical company, announced today that two
studies to be presented this week at the American Pain Society annual meeting
demonstrate the efficacy, tolerability and positive pharmacokinetic profile of
Alpharma Pharmaceuticals&amp;#39; FLECTOR(R) Patch (diclofenac epolamine topical
patch) 1.3%, the first and only prescription anti-inflammatory pain relief
patch in the United States. FLECTOR(R) Patch has been available since January
in the United States for the topical treatment of acute pain due to minor
strains, sprains and contusions.</description>
</item>
                   
<item>
    <title>BEMA(TM) Fentanyl Phase III Data Demonstrating Efficacy and Tolerability to be Presented at American Pain Society Annual Meeting</title>
    <link>http://www.miamiherald.com/965/story/525628.html</link>
    <guid>http://www.miamiherald.com/965/story/525628.html</guid>
    <pubDate>Thu, 08 May 2008 08:23 EDT</pubDate>
    <description>BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and
commercial partner Meda Pharmaceuticals will present today and
tomorrow, data from Phase III clinical pivotal trials for BEMA(TM)
Fentanyl, a potential treatment for breakthrough pain (BTP) in opioid
tolerant patients with cancer. The presentations will be made at the
27th Annual Scientific Meeting of the American Pain Society (APS) in
Tampa, Florida.
</description>
</item>
                   
<item>
    <title>New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain</title>
    <link>http://www.miamiherald.com/965/story/525615.html</link>
    <guid>http://www.miamiherald.com/965/story/525615.html</guid>
    <pubDate>Thu, 08 May 2008 08:08 EDT</pubDate>
    <description> Patients treated with lacosamide
demonstrated sustained pain relief from diabetic neuropathic pain (DNP),
compared to placebo-treated patients, according to data presented at the 27th
annual meeting of the American Pain Society (APS) in Tampa, Fla.</description>
</item>
             

            
    </channel>
</rss>